Newer BPH technologies: iTind, Optilume, Zenflow Spring, and ProVee

iTind: temporary mechanical remodeling

iTind is deployed in the prostatic urethra and bladder neck, remains for roughly five to seven days, and is then removed. Its nitinol struts create pressure at selected points without leaving a permanent implant or ablating tissue.

Randomized evidence supports symptom improvement in selected men, but the dataset and provider network are smaller than for TURP, PUL, or WVTT. Middle-lobe configuration and prostatic urethral length matter. Patients must be comfortable returning for removal and living with the device temporarily.

Optilume BPH: dilation plus paclitaxel

Optilume first dilates the prostatic urethra, then uses a paclitaxel-coated balloon to maintain separation and limit regrowth. The FDA approved it in 2023 for obstructive BPH symptoms in men 50 and older.

Four-year cohort follow-up is available, while FDA post-approval studies continue. Because paclitaxel is transferred locally, the current device labeling—including reproductive precautions and contraindications—should be reviewed directly rather than reduced to a generic “balloon procedure” description.

Zenflow Spring and ProVee: late-2025 implant approvals

The FDA approved two additional prostatic implant systems in December 2025. Zenflow Spring is labeled for prostate volumes 25–80 cc and prostatic urethral lengths 25–45 mm. ProVee is labeled for 30–80 cc glands with a prostatic urethral length of at least 3.75 cm.

Both entered the market with mandatory long-term post-approval follow-up still ahead. Early adopters should disclose training, implant-removal experience, device-specific contraindications, coverage, and how the implant would affect future TURP, HoLEP, MRI, or another device.

A five-part maturity test

• Regulatory status: cleared or approved for what exact age, size, and anatomy?
• Evidence: randomized against sham, compared with an active treatment, or only a single-arm cohort?
• Follow-up: how many patients remain at three, five, and ten years?
• Capability: how many trained programs can actually provide the procedure and manage failure?
• Access: is there a stable code and predictable commercial or Medicare coverage?

When a newer option may be rational

A newer treatment can be reasonable when its mechanism directly matches a high-value priority—such as avoiding tissue ablation or preserving ejaculation—and the patient explicitly accepts shorter follow-up and uncertain retreatment risk.

It is less rational when novelty itself is the selling point, when established options have not been discussed, or when a practice cannot explain its rescue pathway if the device fails.